Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size.
The consumption of pomegranate juice (PJ), a rich source of antioxidant polyphenols, has grown tremendously due to its reported health benefits. Pomegranate extracts, which incorporate the major antioxidants found in pomegranates, namely, ellagitannins, have been developed as botanical dietary supplements to provide an alternative convenient form for consuming the bioactive polyphenols found in PJ. Despite the commercial availability of pomegranate extract dietary supplements, there have been no studies evaluating their safety in human subjects. A pomegranate ellagitannin-enriched polyphenol extract (POMx) was prepared for dietary supplement use and evaluated in two pilot clinical studies. Study 1 was designed for safety assessment in 64 overweight individuals with increased waist size. The subjects consumed either one or two POMx capsules per day providing 710 mg (435 mg of gallic acid equivalents, GAEs) or 1420 mg (870 mg of GAEs) of extracts, respectively, and placebo (0 mg of GAEs). Safety laboratory determinations, including complete blood count (CBC), chemistry, and urinalysis, were made at each of three visits. Study 2 was designed for antioxidant activity assessment in 22 overweight subjects by administration of two POMx capsules per day providing 1000 mg (610 mg of GAEs) of extract versus baseline measurements. Measurement of antioxidant activity as evidenced by thiobarbituric acid reactive substances (TBARS) in plasma were measured before and after POMx supplementation. There was evidence of antioxidant activity through a significant reduction in TBARS linked with cardiovascular disease risk. There were no serious adverse events in any subject studied at either site. These studies demonstrate the safety of a pomegranate ellagitannin-enriched polyphenol dietary supplement in humans and provide evidence of antioxidant activity in humans.
Heber
David
D
Center for Human Nutrition, University of California, Los Angeles, CA 90095, USA. dheber@mednet.ucla.edu
Seeram
Navindra P
NP
Wyatt
Holly
H
Henning
Susanne M
SM
Zhang
Yanjun
Y
Ogden
Lorraine G
LG
Dreher
Mark
M
Hill
James O
JO
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D003257:Consumer Product Safety; D019587:Dietary Supplements / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005419:Flavonoids / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D047348:Hydrolyzable Tannins / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D029561:Lythraceae / Q000009:adverse effects / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D010636:Phenols / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D059808:Polyphenols; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D016896:Treatment Outcome
D000975:Antioxidants; D005419:Flavonoids; D047348:Hydrolyzable Tannins; D010636:Phenols; D059808:Polyphenols; D017392:Thiobarbituric Acid Reactive Substances; C013515:ellagitannin